A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment

BACKGROUND: Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, an HDAC inhibitor epigenetically reversed the resistance of cancer cells to trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Bora, Murthy, Rashmi K., Lee, Jangsoon, Jackson, Summer A., Iwase, Toshiaki, Davis, Darren W., Willey, Jie S., Wu, Jimin, Shen, Yu, Tripathy, Debu, Alvarez, Ricardo, Ibrahim, Nuhad K., Brewster, Abenaa M., Barcenas, Carlos H., Brown, Powel H., Giordano, Sharon H., Moulder, Stacy L., Booser, Daniel J., Moscow, Jeffrey A., Piekarz, Richard, Valero, Vicente, Ueno, Naoto T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738035/
https://www.ncbi.nlm.nih.gov/pubmed/31097774
http://dx.doi.org/10.1038/s41416-019-0473-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738035/
https://www.ncbi.nlm.nih.gov/pubmed/31097774
http://dx.doi.org/10.1038/s41416-019-0473-y

Ejemplares similares